Brokerages Set enGene Holdings Inc. (NASDAQ:ENGN) Target Price at $19.50

enGene Holdings Inc. (NASDAQ:ENGN) has been given an average rating of “Moderate Buy” by the eight brokerages that are presently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating, five have given a buy rating and one has issued a strong buy rating on the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $19.50.

A number of research firms have issued reports on ENGN. HC Wainwright reiterated a “buy” rating and issued a $25.00 target price on shares of enGene in a research note on Monday, September 8th. Weiss Ratings reiterated a “sell (d-)” rating on shares of enGene in a research note on Tuesday, October 14th. Finally, Morgan Stanley cut their target price on shares of enGene from $19.00 to $18.00 and set an “overweight” rating for the company in a research note on Friday, September 12th.

enGene Trading Down 7.3%

NASDAQ ENGN opened at $7.33 on Monday. enGene has a 12 month low of $2.65 and a 12 month high of $9.65. The company has a debt-to-equity ratio of 0.09, a current ratio of 10.34 and a quick ratio of 10.34. The company has a market capitalization of $375.22 million, a price-to-earnings ratio of -3.86 and a beta of -0.27. The company’s fifty day moving average price is $6.71 and its two-hundred day moving average price is $4.74.

enGene (NASDAQ:ENGN) last posted its quarterly earnings results on Thursday, September 11th. The company reported ($0.57) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.06). As a group, research analysts predict that enGene will post -1.56 earnings per share for the current fiscal year.

Institutional Trading of enGene

A number of hedge funds have recently modified their holdings of ENGN. PFS Partners LLC bought a new position in shares of enGene during the 3rd quarter worth approximately $61,000. Paloma Partners Management Co bought a new position in enGene in the second quarter valued at about $38,000. Affinity Asset Advisors LLC bought a new stake in shares of enGene during the second quarter worth about $280,000. Cresset Asset Management LLC bought a new stake in shares of enGene during the second quarter worth about $36,000. Finally, Adage Capital Partners GP L.L.C. lifted its stake in shares of enGene by 2.7% in the first quarter. Adage Capital Partners GP L.L.C. now owns 1,571,642 shares of the company’s stock worth $7,041,000 after acquiring an additional 41,874 shares during the period. 64.16% of the stock is currently owned by institutional investors and hedge funds.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.